Cargando…

Parkinson’s disease managing reversible neurodegeneration

Traditionally, the Parkinson’s disease (PD) symptom course has been classified as an irreversible progressive neurodegenerative disease. This paper documents 29 PD and treatment-induced systemic depletion etiologies which cause and/or exacerbate the seven novel primary relative nutritional deficienc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hinz, Marty, Stein, Alvin, Cole, Ted, McDougall, Beth, Westaway, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827589/ https://www.ncbi.nlm.nih.gov/pubmed/27103805 http://dx.doi.org/10.2147/NDT.S98367

Ejemplares similares

Parkinson’s disease-associated melanin steal
por: Hinz, Marty, et al.
Publicado: (2014)

Parkinson’s disease: carbidopa, nausea, and dyskinesia
por: Hinz, Marty, et al.
Publicado: (2014)

The Parkinson’s disease death rate: carbidopa and vitamin B6
por: Hinz, Marty, et al.
Publicado: (2014)

Management of L-dopa overdose in the competitive inhibition state
por: Hinz, Marty, et al.
Publicado: (2014)

Amino acid management of Parkinson’s disease: a case study
por: Hinz, Marty, et al.
Publicado: (2011)

Administration of supplemental L-tyrosine with phenelzine: a clinical literature review
por: Hinz, Marty, et al.
Publicado: (2014)

Parkinson’s disease managing reversible neurodegeneration [Corrigendum]
Publicado: (2016)

Parkinson’s Disease Managing Reversible Neurodegeneration [Retraction]
Publicado: (2020)

Parkinson’s Disease Managing Reversible Neurodegeneration [Expression of Concern]
Publicado: (2020)

APRESS: apical regulatory super system, serotonin, and dopamine interaction
por: Hinz, Marty, et al.
Publicado: (2011)

Relative nutritional deficiencies associated with centrally acting monoamines
por: Hinz, Marty, et al.
Publicado: (2012)

The discrediting of the monoamine hypothesis
por: Hinz, Marty, et al.
Publicado: (2012)

Monoamine depletion by reuptake inhibitors
por: Hinz, Marty, et al.
Publicado: (2011)

The dual-gate lumen model of renal monoamine transport
por: Hinz, Marty, et al.
Publicado: (2010)

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
por: Hinz, Marty, et al.
Publicado: (2010)

Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine
por: Hinz, Marty, et al.
Publicado: (2011)

Amino acid-responsive Crohn’s disease: a case study
por: Stein, Alvin, et al.
Publicado: (2010)

Neurotransmitter testing of the urine: a comprehensive analysis
por: Hinz, Marty, et al.
Publicado: (2010)

Microperforation prolotherapy: a novel method for successful nonsurgical treatment of atraumatic spontaneous anterior sternoclavicular subluxation, with an illustrative case
por: Stein, Alvin, et al.
Publicado: (2011)

Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model”
por: Hinz, Marty, et al.
Publicado: (2011)

5-HTP efficacy and contraindications
por: Hinz, Marty, et al.
Publicado: (2012)

Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation
por: Hinz, Marty, et al.
Publicado: (2011)

Neurodegeneration and neuroprotection in Parkinson's disease /
Publicado: (1996)

Resource management
por: McDougall, Richard
Publicado: (1999)

Cyclooxygenase and Neuroinflammation in Parkinson’s Disease Neurodegeneration
por: Bartels, Anna L, et al.
Publicado: (2010)

Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease
por: Gelders, Géraldine, et al.
Publicado: (2018)

Sequence of clinical and neurodegeneration events in Parkinson’s disease progression
por: Oxtoby, Neil P, et al.
Publicado: (2021)

Continuity of Constitutional Government during a Pandemic: Considering the Concept in Canada's Emergency Management Act
por: McDougall, Andrew
Publicado: (2020)

Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism
por: Timmons, J. G., et al.
Publicado: (2021)

Parkinson's Disease and Neurodegeneration: GABA-Collapse Hypothesis
por: Błaszczyk, Janusz W.
Publicado: (2016)

Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease
por: Zeng, Xian-Si, et al.
Publicado: (2018)

The Role of LRRK2 in Neurodegeneration of Parkinson Disease
por: Rui, Qin, et al.
Publicado: (2018)

Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
por: Marogianni, Chrysoula, et al.
Publicado: (2020)

Microbial BMAA and the Pathway for Parkinson’s Disease Neurodegeneration
por: Nunes-Costa, Daniela, et al.
Publicado: (2020)

Association of p53 with Neurodegeneration in Parkinson's Disease
por: Luo, Qiang, et al.
Publicado: (2022)

Shared Mechanisms of Neurodegeneration in Alzheimer's Disease and Parkinson's Disease
por: Xie, Anmu, et al.
Publicado: (2014)

Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson’s disease
por: Thomas, George E C, et al.
Publicado: (2021)

Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinson’s Disease
por: Spiegel, Jörg, et al.
Publicado: (2007)

Brain Mitochondrial Dysfunction in Aging, Neurodegeneration, and Parkinson's Disease
por: Navarro, Ana, et al.
Publicado: (2010)

Editorial: Protein Degradation Pathways in Parkinson's Disease and Neurodegeneration
por: Volta, Mattia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hmaqn71s53fekmrobprraa7hbh